Benjamin Graham fit · Defensive deep-value investing
Is Amicus Therapeutics, Inc. (FOLD) a Benjamin Graham Stock?
Meets 2/7 Graham criteria - partially qualifies.
66/100
DNot a fit
2/7 criteria passed
+2 sector-quality lift. Top-quintile within its sector on 1 of 5 quality metrics. Raw pillar score 64 → lifted to 66 before grade derivation.
Capped from B to D. Net income negative for most of the last 5 years - Graham required earnings stability What are deal-breaker caps?
Benjamin Graham's Criteria, Applied to FOLD
P/E ≤ 15
key-
P/B ≤ 1.5
key16.3x
Current ratio ≥ 2
2.8x
Debt / Equity ≤ 1
1.8x
How FOLD Scores on Other Strategies
Live Financial Snapshot
Market cap
-
P/E (TTM)
-
ROIC (TTM)
-
Gross margin
-
Other Benjamin Graham fit reports
Frequently Asked Questions
What is FOLD's Benjamin Graham fit score?
FOLD scores 66/100 on our Benjamin Graham fit engine - grade D. Meets 2/7 Graham criteria - partially qualifies.
Does Benjamin Graham actually own FOLD?
Our score is computed from financial fundamentals against Benjamin Graham's published criteria. We don't claim that Benjamin Graham personally owns or recommends FOLD.
How often is this score updated?
FOLD's Benjamin Graham fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Benjamin Graham personally owns or recommends FOLD.